Integration of metabolomics, lipidomics and clinical data using a machine learning method

Animesh Acharjee, Zsuzsanna Ament, James A. West, Elizabeth Stanley and Julian L. Griffin

From Statistical Methods for Omics Data Integration and Analysis 2015
Valencia, Spain. 14-16 September 2015

Abstract

Background: The recent pandemic of obesity and the metabolic syndrome (MetS) has led to the realisation that new drug targets are needed to either reduce obesity or the subsequent pathophysiological consequences associated with excess weight gain. Certain nuclear hormone receptors (NRs) play a pivotal role in lipid and carbohydrate metabolism and have been highlighted as potential treatments for obesity. This realisation started a search for NR agonists in order to understand and successfully treat MetS and associated conditions such as insulin resistance, dyslipidaemia, hypertension, hypertriglyceridaemia, obesity and cardiovascular disease. The most studied NRs for treating metabolic diseases are the peroxisome proliferator-activated receptors (PPARs), PPAR-α, PPAR-γ, and PPAR-δ. However, prolonged PPAR treatment in animal models has led to adverse side effects including increased risk of a number of cancers, but how these receptors change metabolism long term in terms of pathology, despite many beneficial effects shorter term, is not fully understood. In the current study, changes in male Sprague Dawley rat liver caused by dietary treatment with a PPAR-pan (PPAR-α, −γ, and −δ) agonist were profiled by classical toxicology (clinical chemistry) and high throughput metabolomics and lipidomics approaches using mass spectrometry.

Results: In order to integrate an extensive set of nine different multivariate metabolic and lipidomics datasets with classical toxicological parameters we developed a hypotheses free, data driven machine learning approach. From the data analysis, we examined how the nine datasets were able to model dose and clinical chemistry results, with the different datasets having very different information content.

Conclusions: We found lipidomics (Direct Infusion-Mass Spectrometry) data the most predictive for different dose responses. In addition, associations with the metabolic and lipidomic data with aspartate amino transaminase (AST), a hepatic leakage enzyme to assess organ damage, and albumin, indicative of altered liver synthetic function, were established. Furthermore, by establishing correlations and network connections between eicosanoids, phospholipids and triacylglycerols, we provide evidence that these lipids function as a key link between inflammatory processes and intermediary metabolism.

* Correspondence: Jules.Griffin@mrc-hnr.cam.ac.uk; jlg40@cam.ac.uk
† Equal contributors
1 Medical Research Council, Elsie Widdowson Laboratory, 120 Fulbourn Road, Cambridge CB1 9NL, UK
2 The Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, UK

© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

The metabolic syndrome (MetS) and its associated conditions such as insulin resistance, dyslipidaemia, hypertension, hypertriglyceridaemia, and obesity are all considered global health problems, and contribute to cardiovascular disease and increased mortality and morbidity [1]. Beneficial effects for the treatment of diabetes and MetS by peroxisome proliferator-activated receptors (PPARs) are well established [2]. However, considerable controversy remains about their general safety and side effects in the liver, the cardiovascular system and skeletal muscle. The search for new, and less toxic agonists are of prime importance and several new strategies are being explored to overcome undesirable treatment effects, such as increased risks associated with certain cancers when administered long term in animal models. One such strategy has been the simultaneous activation of two or three (−pan) PPAR receptors in order to favourably influence pathways associated with MetS, while negating some of the side effects such as increased adiposity caused by PPAR-γ agonists. Compound development, where inhibition or activation of enzymes beyond what would be considered the primary PPAR targets are also being explored, including PPAR-pan treatment alongside Sirtuin (SIRT 1) activation [3], or the use of PPAR-pan activators in conjunction with cyclooxygenase (COX) inhibition [4]. The development of better delivery systems such as the use of nanocapsules are also being explored [5].

In the current study, the effects of a PPAR-pan agonist on liver metabolism was investigated after dietary treatment of male Sprague–Dawley (SD) rats. Classical toxicological tests (clinical chemistry) and mass spectrometry (MS) approaches for metabolomic and lipidomic [6] changes were used to provide a ‘deep phenotype’ for the animals. High-throughput ‘-omic’ technologies have gained much interest in recent years and have been previously employed in order to unravel disease mechanisms associated with MetS [7–10].

Despite technological advancement within metabolomics, there are still limitations with the approach. Not only does the diverse and structurally complexity of many metabolomes remain a challenge, the understanding, interpretation and integration of large datasets in conjunction with classical toxicological parameters is a major task. An integrative approach is needed in order to understand the principles underlying the metabolic regulation of a system and how their combined interactions associate with variation in clinical phenotypes results in pathophysiology. This challenge demands new data exploration strategies such as analysis workflows, statistical and computational algorithms for data integration, filtering, and network analysis if we are truly going to be able to convert the large multivariate data collected during such metabolomic experiments into new biological knowledge.

Here we applied a machine learning approach called Random Forest (RF) [11], which is able to integrate multiple data types and successfully combine classical chemical and toxicology test results with multivariate metabolomic and lipidomic data. Several authors have previously adapted RF methods for data integration (also referred to as data fusion) including Acharjee et al., who applied a RF approach to integrate transcriptomics and metabolomics data in plant spices [12], and Fortino et al., who developed and evaluated a fuzzy logic combination with RF to prioritize the candidate discriminant features from gene expression data [13]. Briefly, a RF is a collection of decision trees (ensembles) where each tree gets a “vote” in classifying the sample and find patterns in the data. While RF approaches are very powerful for multivariate datasets, currently they are scarcely applied in metabolomic studies [14]. In the present study, RF classification was used to select subsets of metabolites from a ‘real life’ metabolomics study showing that this statistical approach is successful in building associations and predicting different doses in a drug safety assessment environment. Next, an RF regression approach was used to link liver metabolites with classical clinical chemistry parameters measured from plasma. An integrated network analysis was performed providing a relatively small set of interrelated metabolites which were predictive of dose levels, whilst also aiding understanding of the metabolic processes involved in the study. Metabolites selected in this way provide a useful starting point to understand the underlying effects of PPAR-pan treatment and also aided the generation of hypotheses to be further investigated using more targeted analyses. In addition to exploring the selected metabolites and their known relationships to the PPAR system, one of the emerging hypotheses from our analyses, the central role of eicosanoids (and other oxygenated metabolites of polyunsaturated fatty acids) following PPAR-pan action, were followed up by using an additional MS method for the detection of eicosanoids in the subset of the samples biologically validating our approach. For the purposes of this article we have used the term lipid mediators to encompass both classical eicosanoids and oxidized lipids that are shorter and longer than arachidonic acid.

Methods

All the datasets and protocols used for generating them are based on the Ament et al., [15] manuscript where we have previously published the study design and some of the metabolomics data. These are briefly outlined below, along with the description of the RF data fusion approach used in the present study.
Chemicals
Aqueous metabolite standards were purchased from Sigma Aldrich (Poole, Dorset, UK). Lipid standards were purchased from Avanti-Polar lipids (Alabaster, Alabama, US) with the exception of the standard mix containing 37 fatty acid methyl esters (FAMEs) (Sigma Aldrich, Poole, Dorset, UK). Deuterated compounds used as internal standards were purchased from Cambridge Isotope Laboratories (Andover, Massachusetts, US). Solvents used were of HPLC grade or higher. All other compounds, chemicals and solutions used are detailed where relevant.

Animal experiments and study design
All animal studies were ethically reviewed and carried out in accordance with the Animals (Scientific Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Animals.

The PPAR-pan activator was administered to male Sprague–Dawley rats (CrI:CD (SD) strain), 12 animals per group, by daily oral gavage at 30,100, 300, 1000 mg/kg/day for 13 weeks. A separate satellite group of animals (6 per group) were kept for a 4 week treatment free period in the control, intermediate 2 (300 mg/kg/day) and high (1000 mg/kg/day) dose groups. The detailed number of animals used and doses are shown in Table 1. Rats of the CrI:CD (SD) strain were obtained from Charles River UK Ltd to provide 78 healthy animals which were randomly allocated to study groups. They were acclimatised for approximately 3 weeks and a veterinary inspection was performed before the start of dosing. On Day one of treatment, the rats were approximately 7 weeks old. The study design is summarised in Fig. 1a and 1b. The number of the recovery animals were decided in accordance with the principles of the 3Rs (replacement, reduction and refinement) and only six animals were used in each group in order to minimise the number of animals killed.

Plasma samples for clinical chemistry analysis
Blood samples were taken from the lateral caudal vein using lithium heparin anticoagulant at weeks 4 and 13. Samples were mixed gently and placed on wet-ice until centrifugation. The resultant plasma was separated and rated and the extraction procedure was repeated. Samples were mixed thoroughly, immediately frozen and stored at −80 °C.

In total 34 parameters were measured, among which were aspartate aminotransferase, alkaline phosphatase, potassium, inorganic phosphorus, total protein, total cholesterol, urea, and alanine aminotransferase. Further, relative liver weight was measured which is the ratio between the measured body weight and the measured liver weight of each animal. A complete list of clinical chemistry and their full descriptions can be found in Additional file 1.

Tissue samples
Tissue samples were collected following an overdose of anaesthetic (halothane Ph. Eur. Vapour). Samples of the liver were immediately removed, weighed, and sections snap-frozen in liquid nitrogen. Samples were maintained at −80 °C until further analysis.

An array of analytical methods were used to examine the metabolomic and lipidomic profile of tissues, including gas-chromatography mass-spectrometry (GC-MS), direct infusion mass spectrometry (DI-MS) and liquid chromatography tandem mass spectrometry (LC-MS/MS). Ten datasets were generated comprising of hepatic total fatty acids by GC-MS, intact lipids by DI-MS (positive and negative mode), intact lipids by LC-MS/MS (positive and negative mode), acyl-carnitines, eicosanoids and targeted aqueous metabolites, aqueous open profile (positive and negative mode), comprising approximately 1000 variables.

Liquid-liquid extraction procedures from liver samples
Methanol: chloroform solution (2:1, 600 µL) along with a stainless steel ball (Qiagen, Hilden, Germany) was added to approximately 50 mg of frozen tissue and homogenised with a Tissue Lyser (Qiagen, Hilden, Germany). Chloroform and water (200 µL each) were added, samples were sonicated for 15 min and centrifuged (13 500 rpm, 20 min). The resulting aqueous and organic layers were separated and the extraction procedure was repeated.

The resulting aqueous and organic layers were separated and the extraction procedure was repeated. Samples were dried under nitrogen before processing for GC-MS and LC-MS. GC-MS, and LC-MS/MS methods for lipid extraction and analysis were carried out according to methods previously described [16, 17]. Methods published in previous publications are also provided as supplementary for convenience (Additional file 2). Those methods that are unpublished are detailed below.

Analysis of intact lipids by direct infusion mass spectrometry (DI-MS)
An aliquot of 30 µL of the organic stock solution was added to 20 µL of internal standard mix in methanol:
chloroform (1:1). The internal mix represents different classes of lipids that are used to check mass accuracy to aid identification of lipids species (2.5 μM 1,2-di-o-octadec-cyl-sn-glycero-3-phosphocholine, 5 μM 1,2-di-o-Phytanyl-sn-glycero-3-phosphoethanolamine, 2.5 μM C8-ceramide, 2.5 μM N-heptadecanoyl-D-erythro-phingosylphosphoryl-choline 25 μM undecanoic acid, 2.5 μM trilaurin and 5 μM β-sitosterol acetate). Of the resulting solution, 20 μL was transferred to a glass coated 96 well plate each containing 80 μL 15 mM ammonium acetate in 2:1 isopropanol: methanol. The instrumentation comprised of an Exactive Orbitrap Mass Spectrometer (Thermo Scientific, Hemel Hempstead, Hertfordshire, UK) coupled to a robotic nanoflow TriVersa Nanomate ion source (Advion Biosciences, Ithaca, NY, US) using nanoelectrospray chips with a spraying nozzle diameter of 4.1 μm.

Mass spectrometry data was collected for 1 min in positive ionisation (+1.5 kV) mode followed by 1 min in negative ionisation (−1.5 kV) mode. The ion transfer capillary was set at a temperature of 250 °C for negative ionisation mode and 225 °C for positive ionisation mode. For every ten samples one blank and one pooled sample were added to ensure quality control.

**LC-MS/MS analysis for the open (non-targeted) profiling of aqueous metabolites**

For LC-MS/MS analysis of small molecules, aqueous phase metabolites resulting from the chloroform-methanol extraction were used. The entire fraction was dissolved in 300 μl of 70:30 acetonitrile: water containing 20 μM universally 13C- and 15N-labelled glutamate and 20 μM universally labelled succinate. Samples were vortex mixed, sonicated, centrifuged (17,000 × g, 5 min) and pipetted into auto sampler vials. Chromatographic analyses were performed using an Acquity Ultra Performance Liquid Chromatography (UPLC) system with an Acquity UPLC BEH amide 1.7 μm column (2.1 × 100 mm) coupled to a Xevo-G2 Quadrupole Time-of-Flight (Q-ToF) with a Z-spray electrospray source (Waters Corporation, Elstree, Hertfordshire).

The mobile phase gradient was run at 0.6 mL/min using mobile phase A containing 0.05 % ammonium hydroxide in 10 mM ammonium acetate; mobile phase B was acetonitrile. The initial mobile phase comprised 10 % A. This was subsequently increased to 50 % A over 7 min, after which the gradient was returned to 10 % A for 3 min. Data were acquired in both positive and negative ionisation modes using a source temperature of 150 °C and a desolvation temperature of 300 °C. The desolvation gas flow was 700 L/h and the acquisition mass range was 50–1500 m/z.

For automated peak-picking MarkerLynx™ within the software suite MassLynx™ (version 4.1) by Waters Ltd. (Elstree, Hertfordshire, UK) was used. Mass to charge ratio and intensity pairs were normalised to the internal standard glutamine [U- 13C, 15N] in positive ionisation mode and to universally labelled 13C-succinate in negative ionisation mode. For identification, exact mass data were searched against the metabolite mass spectral database METLIN (http://metlin.scripps.edu/metabo_advanced.php).

The final data set from this analysis was autoscaled for further analysis. Autoscaled variables have a mean of zero and a variance (and also standard deviation) of one, thereby giving all variables (metabolites) an equal weight in the analysis. The analysis methodology is shown in Fig. 2.

**Availability of data**
List of lipidomics, metabolomics and clinical chemistry data set are provided in the Additional file 3.

**Random forest**
We used Random Forest (RF) for data fusion which is a machine learning ensemble method in conjunction with multiple learning algorithms to obtain better predictive
The major difference between machine learning and linear methods is that, linear methods assume all metabolites are combined in a linear way and then impact on the outcome, for example control compared with high dose, whereas RF does not assume any linearity and rather uses the sum of piecewise functions, and hence is able to discover more complex dependencies. RF can be used for both classification and regression [11] based analysis on the data we have generated in this study. For example using liver metabolites (GC-MS, LC-MS/MS, DI-MS) and plasma clinical chemistry datasets to classify the different dose groups and also cross-correlating between the different datasets. Random Forest (RF) uses a bootstrapping method for training or testing and decision trees for prediction. The bootstrapping process generates random samples from the dataset with replacement. Every bootstrapped sample has a corresponding left out or ‘out-of-bag’ (OOB) sample which is used to test the routine, and prediction is made on those left out samples.

**Random forest classification**

We used RF as a multiclass classification method using the control group, four different doses, and the three recovery groups as different classes, whilst metabolomic and lipidomic mass spectrometry data (acyl carnitines, aqueous metabolites, DI-MS, GC-MS, intact lipids) were treated as the predictor sets separately.

RF needs to use the number of trees (ntree) and number of variables (metabolites) randomly sampled as candidates at each split (mtry), and these parameters need to be defined. We used ntree = 500 and mtry = square root of variables in our models. For example, for the acyl carnitines data set, the mtry value was set to the nearest integer to the square root of 40 which is 6. Choosing the parameters was done based on the method described by Liaw and Wiener, 2002 [18].

**Random forest regression**

RF was used for regression of the classical clinical chemistry phenotypic traits with the metabolomic and lipidomic mass spectrometry data (acyl carnitines, aqueous metabolites, DI-MS, GC-MS, and intact lipids) being treated as predictor sets separately. RF constructs a predictive model for each of the response clinical phenotypes, whilst qualifying the importance of each variable. In this case the aqueous and organic metabolites, and their ability to explain the variation present in the classical clinical chemistry phenotypes. We quantified the RF regression model based on the variation explained by the model. The variation explained by RF is not just a measure of the goodness of fit of the data, but is also determined by the left-out samples (the “out-of-bag” samples), so it should be interpreted as a measure of predictive quality (here considered as the $Q^2$). The variance explained in RF is defined as:

$$1 - \text{Mean square error (MSE)/Variance of response},$$

where MSE is the sum of squared residuals of the OOB samples divided by the OOB sample size. Since the MSE...
is estimated on the OOB samples and the total variance on all the samples, $Q^2$ can be negative. RF regression also needs to use some of the parameters used above in the classification models; for example number of trees (ntree), and number of variables (metabolites) randomly sampled as candidates at each split (mtry). We used $ntree = 500$ and $mtry = \text{one third of the variables}$. For example, for the acyl carnitines data set, the mtry value will be one third of 40 which is approximately 13. Choice of these parameters was done based on Liaw and Wiener, 2002 [18].

**The Backward elimination method**

To select metabolites we iteratively fitted random forests, at each iteration building a new forest after discarding 20 % of the metabolites with the smallest variable importance. The selected set of metabolites is used as a predictor to fit the model to check the OOB error rate. This procedure is done iteratively using the varSelRF function from the varSelRF package in R [19].

**Permutation test**

RF quantifies the importance of metabolites that explain the variation present in the clinical phenotypes, but does not give a significance level or a threshold to choose a possible subset of associated metabolites. Therefore, we included a permutation test to indicate significance of the metabolite association in this study. In our situation, we randomized all clinical phenotypes separately and each time applied RF. The RF model was applied 1000 times for 1000 different randomizations of the clinical phenotypes and in each analysis we estimated the variance explained by the RF model ($Q^2$) and variable importance of all variables in terms of a decrease in node impurities. We ordered node purity values from the permuted data sets and took the 95 percentile from the distribution impurity values for node impurity to assess the significance of the of individual genes and metabolites. The same was done for $Q^2$ values of the model: the 95 percentile was used as a cut-off to denote significance of the $Q^2$ value in RF regression.

For classification purposes, we used backward selection and for regression, we used a permutation test for assessing the significance of the metabolites.

**Network analysis**

A network is a set of nodes and a set of edges, where each node represents either a metabolite or classical clinical chemistry parameter, whereas the edges represent associations amongst them. A partial Pearson correlation coefficients were used to quantify the strength of association between combinations of metabolites or clinical chemistry parameters. A significance threshold of $\alpha = 0.05$ was used to draw edges between the selected nodes. We used the partial correlation because it measures the correlation between two variables after their linear dependence on other variables is removed. It can distinguish between direct and indirect associations whereas correlation-based network cannot and often yield many spurious edges [20]. Partial correlation analysis was done using the ppcor package in R [21].

**Software**

All statistical and network analysis was done in using R software (v3.2.1). We used two R packages for Random forest analysis: randomForest and varSelRF. The R-Scripts are provided in the Additional file 4.

**Result and discussion**

**Random forest (RF) classification identifies the most informative mass spectrometry platforms for determining dose response effects**

Using the RF classification approach, four different doses in addition to the control and the three recovery groups were treated as multiclass parameters, whilst metabolomic and lipidomic mass spectrometry data were treated as predictor sets. OOB misclassification error rates were calculated for the individual datasets. DI-MS in positive ionisation mode, measuring primarily glycerophospholipids and glycerolipids, was found to have the lowest OOB errors of 36 % and hence the most informative compared to other datasets, whilst aqueous open profiling (positive mode) metabolite analysis data resulted in the highest class error of 72 % and was therefore the least predictive of dose levels administered (Fig. 3a). Across the different metabolite datasets the most discriminatory metabolites were selected using a backward elimination approach (Fig. 3b) [19]. The number of selected metabolites, were surprisingly small, making the data matrix considerably smaller and most importantly, simplifying the biological information needed to be considered. The selected subset of metabolites were used to re-calculate the OBB misclassification errors and it was found that the class error improved in eight out of nine datasets using these reduced datasets (Fig. 3a). Variable selection using RF classification is a rapid, and an effective approach that allows one to comprehend the complexity of the data matrix. (relative concentration changes of the selected variables are displayed using box plots and are provided in Additional file 5). The selected metabolites from the RF analysis (56 in total) were combined, and re-subjected to the RF classification approach. The OOB error rates improved to 22 % (from 36 % for the best dataset considered on its own previously): whilst re-applying a backward elimination process the most discriminatory variables reduced to 12 and lowered the OOB error even further to 21 %.
Partial correlation network analysis as an effective tool for visualising metabolic pathways

As a next data processing step, the partial correlation between the selected 12 metabolites were calculated. The generated network figure (Fig. 4) provides an interpretable and useful view of metabolite connections.

Four broad themes emerged from the analysis. Firstly, the selected 12 metabolites include only lipids, and no aqueous compounds, reflecting the intimate role of PPARs in lipidomic remodelling. Secondly, changes in acyl-carnitines (C4-DC and C5:1) are suggestive of potential aciduria [22]. The building up in aciduria comes from increased glycolysis and production of lactate as a result of impaired mitochondria. As PPARs are known to regulate mitochondrial and peroxisomal lipid metabolism, and aciduria is commonly reported in mitochondrial disorders, this suggests common pathophysiological mechanism of damage. Thirdly, we noted that metabolites C20:3, C20:5, C22:5 are all precursors of eicosanoids or lipid mediators that can act as signalling molecules. Furthermore, all phospholipids highlighted by our RF approach contain at least four double bonds, and hence these species also potentially feed into the arachidonic acid cascade and eicosanoid production. Changes in PCs with at least four double bonds, most likely represent lipid remodelling to generate eicosanoid species derived from arachidonic acid.
Finally, the odd chain saturated fatty acid: C17:0, commonly considered to be a marker of ruminant fat intake [23], was also found as an important dose predictor and was highly discriminatory, leading us to further speculate on suggestions linking this fatty acid to fatty acid α-oxidation [23], possibly in peroxisomes.

The RF regression approach for understanding toxicology in the era of -omics technologies
Thorough understanding of new methods is essential in order to avoid misinterpretation of data which could lead to false conclusions about a complex biological process like toxicity. Data generation for new biomarkers that are used to characterise and describe cellular responses are growing exponentially in the post genomic era [24]. This information has an unrealised power to provide increased understanding on toxicological outcomes. While the potential of -omic approaches have been realised by regulatory agencies for improving the risk assessment process, the strategy for evaluating cell and tissue damage from a toxic insult has changed very little for almost sixty years [25, 26].

In an attempt to merge metabolomics and lipidomics data with different clinical chemistry phenotypes, such as relative liver weight and plasma clinical chemistry parameters, an RF regression approach was used. First, relative liver weight was examined, and the variation explained by metabolomic and lipidomic datasets in relative liver weight was calculated. Metabolites explaining the variation were filtered out form the rest of the data, and the RF regression calculations were repeated. There were no significant differences in the variations explained (Q^2) when comparing full datasets to only selected metabolites (Fig. 5a), although the number of metabolites driving the variation were much smaller when compared to the full dataset (Fig. 5b). The intact
lipids measured in positive ionisation mode by DI-MS were found to explain the highest variation (84%) with regards to relative liver weight changes and the lowest variation was explained by intact lipid LC-MS data in negative ionisation mode (32%).

The plasma clinical chemistry parameters were investigated in a similar fashion to the relative liver weight, with the exception, that this dataset contains multiple (34) clinical chemistry variables as outcomes, each of which were examined, and the metabolites explaining their variation identified. The highest values for variations explained include aspartate aminotransferase (AST), albumin, glucose and alkaline phosphatase (ALP) resulting in 42, 26, 35 and 27% variation explained (Q²), respectively (Fig. 5c). It is also apparent form the data, that GC-MS of total fatty acids and DI-MS measurement of lipids measured in both positive and negative ionisation modes performed the best in explaining the variation in the parameters (Fig. 5c). A partial correlation network diagram with relative liver weight is

![Figure 5](image-url)
shown in Fig. 6. Information of the other 30 variables assessed is provided in Additional file 6.

The phospholipids explaining the highest variation in relative liver weight are highly unsaturated, and therefore, structurally similar to the lipids identified in the dose response analysis described above. It is likely that these species can feed into the eicosanoid cascade of arachidonic acid metabolism. There are two well-established degradation pathways of highly unsaturated fatty acids, one is the β-oxidation pathway in mitochondria and peroxisomes and the other is the formation of eicosanoids. PPARs play a key role in both metabolic processes. However, we also note, again, an unexpected change in the C17:0 total fatty acid content, which might link the PPAR system to a thus far under-investigated possibility of fatty acid α-oxidation pathway.

Investigation of eicosanoid production from intact lipids:

Biological perspective

In order to validate the changes in lipid mediator precursor fatty acids C20:3, C20:5, C22:5 and their role in predicting dose response, and to investigate the possibility that the highly unsaturated phospholipids feed into the arachidonic acid cascade, an additional dataset was generated focusing on the measurement of eicosanoids. Since dose responses were highly predictable, only a subset of the study samples were analysed, including the control, the intermediate dose 2 (300 mg/kg/day) and the highest dose group (1000 mg/kg/day) samples. Eicosanoids are known to possess pro- or anti-inflammatory properties, and the liver is highly responsive to inflammation as it is densely populated with its own macrophages, the Kupffer cells, which account for over 10% of total liver cells [27]. Importantly, macrophages are elite producers of eicosanoids and other related lipid mediators during inflammation. Kupffer cells not only contribute to the production of inflammatory mediators they have also well-established connections to diet induced hepatic steatosis [28], PPAR-α activation, and non-genotoxic carcinogenesis [16]. From a metabolomics perspective, the role of macrophages in inflammatory signalling is mostly understood in the context of arachidonic acid metabolism. Arachidonic acid (AA; 20:4) is stored in PLs and during inflammation it is hydrolysed by cytosolic phospholipase A2 (cPLA2). It is also well established, that the ubiquitously expressed diacylglycerol kinases (DGKs) phosphorylate sn-1,2-DGs, with several DGKs exhibiting specificity for sn-1,2 DGs containing C20:4 [29, 30]. It is therefore reasonable to assume that a large proportion of PLs storing AA can be synthesised from DGs. On the other hand, precursors of phospholipase C (PLC), which cleaves off phosphoglycerol headgroups of PLs, exhibit a high abundance of C20:4 esterified at the sn-2 position of the glycerol backbone [29, 31].

In order to address the complexity and connections of lipid mediators with PLs and DGs, Pearson correlation and partial correlation analysis was applied using the eicosanoid and the DI-MS datasets for both positive and negative ionisation modes. There were 14 variables with a Pearson correlation ≥ 0.8, and all eicosanoids were found to positively correlate with the intact lipids (Fig. 7a, 7b). For those metabolites partial correlation analysis was performed and only subset of the metabolites found connected. This demonstrates that lipidomic profiling can offer insight about the source of downstream signalling effects in cells.
The central role of the liver in regulating systemic metabolism has put this organ in the spotlight for decades in toxicology, and yet many molecular mechanisms are still mostly unexplored. For example, AA metabolism as highlighted in the current study, and the metabolic concept, that the source of AA for eicosanoid production is based in PLs although widely accepted is being challenged [32]. Indeed, the pathways for AA liberation, how enzymes access their substrates, and how these mechanisms are controlled by PPARs remains essentially unresolved. We have demonstrated above the versatility of lipidomic data integration, and that the investigation of lipid signalling molecules is an important challenge for future research. In addition, our results highlight the need for further mechanistic studies to better understand how lipid remodelling at the gross level (e.g. DI-MS methods) produces changes in lipid signalling molecules such as eicosanoids.

**Conclusions**

In this study, we present a powerful strategy for integrating multiple -omics data using a machine learning algorithm (RF) and selecting discriminatory metabolites for partial correlation network analysis. We used RF regression and classification for integrating metabolomics data sets. In terms of comparing RF to other similar approaches, Scott et al., 2013 [14] studied and tested 28 classifiers on NMR spectroscopy or MS data of different origins as the training sets for various multivariate tools. Data came from four metabolomics or food projects, whose class numbers differed. Random forests performed best on high-dimensional data, but was only used in 4.5 % of papers. This procedure can handle high dimensional data (for example, where the number of metabolites is much larger than the number of samples) and has an internal crossvalidation procedure (using the OOB samples). However, it could be considered a limitation that a RF model by default will use all variables simultaneously and if we want to perform variable selection, we need to set a threshold on the number of variables or we need to select variables based on a significance criterion or a variable selection procedure. The backward elimination procedure implemented in the package varSelRF uses the OOB as minimization criterion. Thus, the OOB performances achieved with the reduced model is likely to be biased; one possible solution would be applying the cross validation based protocol discussed in [33]. We used each of the predictor data separately (Fig. 3a) because we would like to interrogate each of the data sets independently to determine if those datasets are informative or not. If we would have combined the data into a single matrix, we would have missed that information. For example, aqueous open profiling data with all the variables gives rise to more than a 70 % class error. Thus, this data set is probably not useful as it is not predictive enough for a given response variable. This approach will help biologists if they want to perform targeted experiments in the future following an open profiling metabolomics experiment as part of the discovery phase. Thus, this data fusion strategy will help them to identify leads from a huge pool of -omics data sets. To the best of our knowledge, no such integrative approach have been utilised to link classical hepatic parameters with metabolite markers, more accurate and early detection of toxicity can be facilitated. In addition, the presented approach can easily be applied in human to discover novel relationships in multi -omic data sets. In conclusion, our integrative approach offers a good starting point for addressing the complexity of interrelated metabolites, although more studies are needed for validation and to further explore the interrelation between metabolism, signalling, and disease.
Additional files

Additional file 1: List of clinical chemistry analysis performed and their full descriptions. (DOCX 13 kb)

Additional file 2: Method descriptions for GC-MS, LC-MS/MS analysis of intact lipids, targeted analysis of aqueous metabolites and eicosanoids by LC-MS. (DOCX 20 kb)

Additional file 3: List of lipidomics, metabolomics and clinical chemistry data set. (XLXS 897 kb)

Additional file 4: The R- Scripts used in the analysis. (TXT 4 kb)

Additional file 5: Box plot of selected variables using RF classification. (PPTX 104 kb)

Additional file 6: Table of classical toxicology and variation explained (Q2) linking different data sets. (PPTX 60 kb)

Abbreviations

AA: Arachidonic acid; AST: Aspartate transaminase; COX: Cyclooxygenase; cPLA2: Phospholipase A2; cPLA2: Phospholipase C; CYP: Cytochrome P450; DGlKs: Diacylglycerol kinases; DGLA: Dihomo-γ-linolenic acid; Dgs: Diacylglycerides; DHET: Dihydroxyeicosatetraenoic acid; DHOME: Dihydroxyoctadecadienoic acid; DI-MS: Direct infusion mass spectrometry; EI: Electron ionization; EPA: Eicosapentaenoic acid; Enr: Ethanolamine; FAME: Fatty acid methyl esters; GC-MS: Gas-chromatography mass-spectrometry; HEPE: Hydroxyeicosapentaenoic acid; HETE: Hydroxyeicosatetraenoic acid; LA: Linoleic acid; LC-MS/MS: Liquid chromatography mass-spectrometry; HEPE: Hydroxyeicosapentaenoic acid; HETE: Hydroxyeicosatetraenoic acid; LC: Liquid chromatography tandem mass spectrometry; LOX: Lipoxigenase; MetS: Metabolic syndrome; MS: Mass spectrometry; NRs: Nuclear hormone receptors; OOB: Out-of-bag; PC: Phosphocholine; PE: Phosphoethanolamine; PG: Phosphoglycerol; PLs: Phospholipids; PPAR: Peroxisome proliferator-activated receptors; RF: Random forest; SD: Sprague–Dawley; sEH: Soluble-epoxy-hydrolase; SFR1: Siturin 1; SM: Sphingomyelin; TG: Triacylglycerol or triglycerides; THET: Trihydroxyeicosatetraenoic acid; TriHOME: Trihydroxyoctadecenoic acid

Acknowledgements

This work was supported by the MRC programme award Lipid Profiling and Signalling and the Cambridge Initiative in Obesity and Metabolic Disease (Lipid Dynamics and Regulation) (MC_UP_A090_1006) and MRC Supplementary Award Lipidomics and Prevention of type 2 diabetes (MC_PC_13030). The authors would also like to acknowledge GlaxoSmithKline for the generous provision of tissue samples to enable the work. We would also like to acknowledge the anonymous reviewers for their constructive feedback.

Declarations

Publication charges for this article have been funded by MRC programme award Lipid Profiling and Signalling and the Cambridge Initiative in Obesity and Metabolic Disease (Lipid Dynamics and Regulation) (MC_UP_A090_1006 and MC_PC_13030).

This article has been published as part of BMC Bioinformatics Volume 17 Supplement 15. 2016: Proceedings of Statistical Methods for Omics Data Integration and Analysis 2015. The full contents of the supplement are available online at http://bmcbioinformatics.biomedcentral.com/articles/supplements/volume-17-supplement-15.

Authors’ contributions

AA, ZA and JLG wrote the manuscript. AA carried out all the statistical analysis. ZA performed the sample preparation, the LC-MS and GC-MS experiments. JAW developed the targeted aqueous analysis assay. EGS performed the direct infusion data processing. All authors read and approved the manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Published: 22 November 2016

References

1. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014.
2. Ament Z, Masoodi M, Griffin J. Applications of metabolomics for understanding the action of peroxisome proliferator-activated receptors (PPARs) in diabetes, obesity and cancer. Genome Med. 2012;4:32.
3. Chen W, Fan S, Xie X, Xue N, Jin X, Wang L. Novel PPAR pan agonist, ZBH ameliorates hyperlipidemia and insulin resistance in high fat diet induced hyperlipidemic hamster. PLoS One. 2014;9:e96056.
4. Santin JR, Machado ID, Rodrigues SF, Teixeira S, Muscarà MN, Caldino SL, Pitta IR, Farsky SH. Role of an endothelio-thiazolidine molecule PPAR pan-agonist and COX inhibitor on inflammation and microcirculatory damage in acute gastric lesions. PLoS One. 2013;8:e67689.
5. Garcia GM, Oliveira LT, da Rocha R, de Lima MCA, Vilela JMC, Andrade MS, Abdalla DSP, Mosquesora VCF. Improved nonclinical pharmacokinetics and biodistribution of a new PPAR pan-agonist and COX inhibitor in nanocapsule formulation. J Control Release. 2015;209:207–18.
6. Roberts LD, West JA, Vidal-Pugil A, Griffin JL. Methods for performing lipidomics in white adipose tissue. Methods Enzymol. 2014;538:211–31.
7. Chen H, Tseng Y, Wang S, Tsai Y, Chang C, Kuo T, Yao W, Sheih C, Wu C, Kuo P. The metabolome profiling and pathway analysis in metabolic healthy and abnormal obesity. Int J Obes. 2013;39:1241–8.
8. Roberts LD, Jones O. Type 2 Diabetes Mellitus and The Metabolic Syndrome. Metabolomics and Systems Biology in Human Health and Medicine. 2014;141.
9. Willinger CM, Yin X, Juhaz P, Courchesne P, Muntendam P, Gordon N, Adourian A, Laron MG, Levy D. Discovery lipidomic and metabolomic profiling predicts longitudinal changes in metabolic risk factors. Circulation. 2014;130:A18728.
10. Rolim AEH, Henriques-Araújo R, Ferraz EG, Dultra FKA, Fernandez LG. Lipidomics in the study of lipid metabolism: Current perspectives in the omic sciences. Gene. 2015;554:131–9.
11. Breman L. Random forests. Mach Learn. 2001;45:5–32.
12. Acharjee A, Kloosterman B, de Vos RC, Wierij JS, Bacherm OW, Visser RG, Malepepaard C, Data integration and network reconstruction with −omics data using Random Forest regression in potato. Anal Chim Acta. 2011;705:56–63.
13. Fortino V, Kinaret P, Fyrhquist N, Alenius H, Greco D. A robust and accurate method for feature selection and prioritization from multi-class OMics data. PLoS One. 2014;9:e107801.
14. Scott I, Lip, A, Liakata M, Wood J, Vermeer C, Aitaway D, Ward J, Draper J, Beale M, Corol D. Merits of random forests emerge in evaluation of chemometric classifiers by external validation. Anal Chim Acta. 2013;801:22–33.
15. Ament Z, West JA, Stanley E, Ashmore T, Roberts LD, Wright J, Nicholls AW, Griffin JL. PPAR-pan Activation Induces Hepatic Oxidative Stress and Lipidomic Remodelling. Free Radic Biol Med. 2015;95:357–68.
16. Ament Z, Waterman CL, West JA, Stanley EA, Ashmore T, Roberts LD, Wright J, Nicholls AW, Griffin JL. A metabolomics investigation of non-genotoxic carcinogenicity in the rat. J Proteome Res. 2013;12:5775–90.
17. Waterman C, Currie R, Cottrell L, Dow J, Wright J, Waterfield C, Griffin J. An integrated functional genomic study of acute phenobarbital exposure in the rat. BMC Genomics. 2010;11:9–9.
18. Liaw A, Wiener M. Classification and regression by randomForest. Rnews. 2002;8:22–17.
19. Díaz-Uriarte R, De Andres SA. Gene selection and classification of microarray data using random forest. BMC Bioinformatics. 2006;7:3.
20. Zuo Y, Yu G, Tadesse MG, Resmon HW. Biological network inference using low order partial correlation. Methods. 2014;69:266–73.
21. Kim S. gpccor: an R package for a fast calculation to semi-partial correlation coefficients. Commun Stat Appl Methods. 2015;22:665.
22. Rinaldo P, Welch RD, Previs SF, Schmidt-Sommerfeld E, Gargus JJ, O’Shea JJ, Zinn AB. Ethylmalonic/acidic aciduria: effects of oral medium-chain triglycerides, carnitine, and glycine on urinary excretion of organic acids, acylcarnitines, and acylglycines. Pediatr Res. 1991;30:216–21.
23. Jenkins B, West JA, Koulman A. A review of odd-chain fatty acid metabolism and the role of pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0) in health and disease. Molecules. 2015;20:2425-44.
24. Aardema MJ, MacGregor JT. Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "omics" technologies. Mutat Res. 2002;499:13–25.
25. Lehman AJ, Patterson WJ, Davidow B, Hagan EC. Procedures for the appraisal of the toxicity of chemicals in foods, drugs and cosmetics. Food Drug Cosm Lett. 1995;10:679.
26. Barnes J, Denz F. Experimental methods used in determining chronic toxicity: a critical review. Pharmacol Rev. 1954;6:191–242.
27. Esser N, Legrand-Poels S, Prette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105:141–50.
28. Huang W, Metlakunta A, Dedousis N, Zhang P, Sipula I, Dube JJ, Scott DK, O'Doherty RM. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes. 2010;59:347–57.
29. Eichmann TO, Lass A. DAG tales: the multiple faces of diacylglycerol—stereochemistry, metabolism, and signaling. Cell Mol Life Sci. 2015;72:1–22.
30. Epand RM, Shulga YV, Timmons HC, Perri AL, Belani JD, Perinpanathan K, Johnson-McIntire LB, Rajaljeh S, Dicu AO, Elias C. Substrate chirality and specificity of diacylglycerol kinases and the multisubstrate lipid kinase. Biochemistry. 2007;46:14225–31.
31. Wood R, Harlow R. Structural analyses of rat liver phosphoglycerides. Arch Biochem Biophys. 1969;135:272–81.
32. Dichlberger A, Schlager S, Kovanen PT, Schneider WJ. Lipid droplets in activated mast cells—a significant source of triglyceride-derived arachidonic acid for eicosanoid production. Eur J Pharmacol. 2016;785:59–69.
33. Tsamardinos I, Rakhshani A, Lagani V. Performance-estimation properties of cross-validation-based protocols with simultaneous hyper-parameter optimization. Int J Artif Intell Tools. 2015;24:1540023.